|
1
|
Funston G, Van Melle M, Bain ML, Jensen H,
Helsper C, Emery J, Crosbie EJ, Thompson M, Hamilton W and Walter
FM: Variation in the initial assessment and investigation for
ovarian cancer in symptomatic women: A systematic review of
international guidelines. BMC Cancer. 19:10282019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Previs R, Leath CA 3rd, Coleman RL, Herzog
TJ, Krivak TC, Brower SL, Tian C and Secord AA: Evaluation of in
vitro chemoresponse profiles in women with type I and type II
epithelial ovarian cancers: An observational study ancillary
analysis. Gynecol Oncol. 138:267–271. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nhokaew W, Kleebkaow P, Chaisuriya N and
Kietpeerakool C: Programmed Death ligand (PD-L1) expression in
epithelial ovarian cancer: A comparison of I and type II tumors.
Aaian Pac J Cancer Prev. 20:1161–1169. 2019. View Article : Google Scholar
|
|
4
|
Modugno F and Edwards RP: Ovarian cancer:
Prevention, detection, and treatment of the disease and its
recurrence. Molecular mechanisms and personalized medicine meeting
report. Int J Gynecol Cancer. 22:S45–S57. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Webb PM and Jordan SJ: Epidemiology of
epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol.
41:3–14. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Grunewald T and Ledermann JA: Targeted
therapies for ovarian cancer. Best Pract Res Clin Obstet Gynaecol.
41:139–152. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Alto LT and Terman JR: Semaphorins and
their signaling mechanism. Methods Mol Biol. 1493:1–25. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wei L, Li H, Tamagnone L and You H:
Semaphorins and their receptors in hematological malignancies.
Front Oncol. 9:3822019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Neufeld G, Mumblat Y, Smolkin T, Toledano
S, Nir-Zvi I, Ziv K and Kessler O: The semaphorins and their
receptors as modulators of tumor progression. Drug Resist Updat.
29:1–12. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ge C, Li Q, Wang L and Xu X: The role of
axon guidance factor semaphorin 6B in the invasion and metastasis
of gastric cancer. J Int Med Res. 41:284–292. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nenfeld G, Mumblat Y, Smolkin T, Toledano
S, Nir-Zvi I, Ziv K and Kessler O: The role of the semaphorins in
cancer. Cell Adh Migr. 10:652–674. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Word Health Organization (WHO) (2010), .
Treatment of tuberculosis: Guidelines. Fourth Edition.
|
|
13
|
Wittekind C and Sobin LH: TNM
Classification of Malignant Tumors. 5th. Wiley-Liss; New York, NY:
1997
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vadasz Z, Rubinstein J, Bejar J, Sheffer H
and Halachmi S: Overexpression of semaphorin 3A in patients with
urothelial cancer. Urol Oncol. 36:161 e1–161 e6. 2018. View Article : Google Scholar
|
|
16
|
Schaeffer J, Tannahill D, Cioni JM,
Rowlands D and Keynes R: Identification of the extracellular matrix
protein Fibulin-2 as a regulator of spinal nerve organization. Dev
Biol. 442:101–114. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kaitu'u-Lino TJ, Hastie R, Cannon P,
Binder NK, Lee S, Stock O, Hannan NJ and Tong S: Placental SEMA3B
expression is not altered in severe early onset preeclampsia.
Placenta. 35:1102–1105. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rao J, Zhou ZH, Yang J, Shi Y, Xu SL, Wang
B, Ping YF, Chen L, Cui YH, Zhang X, et al: Semaphorin-3F
suppresses the stemness of colorectal cancer cells by inactivating
Rac1. Cancer Lett. 358:76–84. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cao Z, Yu D, Fu S, Zhang G, Pan Y, Bao M,
Tu J, Shang B, Guo P, Yang P and Zhou Q: Lycorine hydrochloride
selectively inhibits human ovarian cancer cell proliferation and
tumor neovascularization with very low toxicity. Toxicol Lett.
218:174–185. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang J, Zeng Z, Qiao L, Jiang X, Ma J,
Wang J, Ye S, Ma Q, Wei J, Wu M, et al: Semaphorin 4C promotes
macrophage recruitment and angiogenesis in breast cancer. Mol
Cancer Res. 17:2015–2028. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gurrapu S, Pupo E, Franzolin G, Lanzetti L
and Tamagonoe L: Sema4C/PlexinB2 signaling controls breast cancer
cell growth, hormonal dependence and tumorigenic potential. Cell
Death Differ. 25:1259–1275. 2018. View Article : Google Scholar : PubMed/NCBI
|
